| Bid | 18.01 |
| Market Cap | 2.24B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -5 |
| PE Ratio (ttm) | -3.61 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 18.3 |
| Volume | 983,673 |
| Avg. Volume (20D) | 1,515,385 |
| Open | 19.04 |
| Previous Close | 18.91 |
| Day's Range | 18.02 - 19.07 |
| 52-Week Range | 17.05 - 36.72 |
| Beta | undefined |
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P...
Analyst Forecast
According to 10 analyst ratings, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 132.82% from the latest price.
Next Earnings Release
Analysts project revenue of $14.09M, reflecting a 296.79% YoY growth and earnings per share of -1.1, making a -11.29% decrease YoY.
1 day ago · https://thefly.com
Sarepta's Elevidys launch remains strong with solid beat, says JPMorganSarepta + Arrowhead +0.18 (+0.97%)
1 month ago · seekingalpha.com
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President & CEO Bruce Given -...
2 months ago · businesswire.com
Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 ConferencesPASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 15th Annual American C...
